Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt
- PMID: 31107367
- DOI: 10.1097/MPH.0000000000001506
Age and Tumor Location Predict Survival in Nonmetastatic Osteosarcoma in Upper Egypt
Abstract
Aim: The aims of this study were to assess survival outcome of pediatric patients with localized osteosarcoma of the extremities in Upper Egypt, identify factors of prognostic significance for survival, and to determine factors predictive of surgical methods used in these patients, as well as developing a clinical model for risk prediction.
Patients and methods: A retrospective analysis of data assembled from medical records of 30 pediatric patients with a histologically verified nonmetastatic osteosarcoma of the extremities treated at South Egypt Cancer Institute with a unified chemotherapy protocol between January 2001 and December 2015 was carried out. Prognostic factors were determined using univariable and multivariable methods. A model for surgical outcomes in these patients based on the baseline clinical factors, and the parameters predictive of their tumor response to chemotherapy, was developed.
Results: With a median follow-up of 63 months for the study population, the estimates for event-free survival and overall survival (OS) at 3 and 5 years were 69.5% and 79% and 65.2% and 65.3%, respectively. Age 16 years or above was independently associated with both worse metastasis-free survival (hazard ratio [HR]=6.05, 95% confidence interval [CI]: 1.43-25.6, P=0.015) and OS (HR=7.9, 95% CI: 1.71-36.2, P=0.008). In the multivariable analysis, a proximal location within the limb gained a statistical significance to be independently associated with worse OS (HR=2.4, 95% CI: 1.13-22.1, P=0.003). Poor response to chemotherapy was marginally associated with worse metastasis-free survival (HR=4.9, 95% CI: 1.02-23.8, P=0.047) only in the univariable analysis. The patients found to be more likely to undergo an amputation surgery (odds ratio=14.1, 95% CI: 1.34-149.4, P=0.028) were those in whom a tumor was poorly responding to chemotherapy.
Conclusion: In Upper Egypt, despite the reasonable survival outcomes in nonmetastatic osteosarcoma, a relatively high limb amputation rate has been encountered. The development of a clinical prediction model for future planning of possible outcome improvement in these patients, however, is still feasible.
Similar articles
-
Pediatric Osteosarcoma of Extremities: A 15-year Experience From a Tertiary Care Cancer Center in Upper Egypt.J Pediatr Hematol Oncol. 2019 Aug;41(6):e371-e383. doi: 10.1097/MPH.0000000000001407. J Pediatr Hematol Oncol. 2019. PMID: 30629005
-
Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival.Ann Surg Oncol. 2015 Apr;22(4):1080-7. doi: 10.1245/s10434-014-4154-z. Epub 2014 Oct 17. Ann Surg Oncol. 2015. PMID: 25323470 Clinical Trial.
-
Chemotherapy-Surgery Interval Effects on Tumor Necrosis and Outcome in Children and Young Adults With Osteosarcoma.Pediatr Blood Cancer. 2025 Mar;72(3):e31466. doi: 10.1002/pbc.31466. Epub 2024 Dec 9. Pediatr Blood Cancer. 2025. PMID: 39654083
-
Neoadjuvant chemotherapy for patients with osteosarcoma: University of Florida studies.Cancer Treat Res. 1993;62:339-46. doi: 10.1007/978-1-4615-3518-8_41. Cancer Treat Res. 1993. PMID: 8096749 Review. No abstract available.
-
Childhood osteosarcoma: multimodal therapy in a single-institution Turkish series.Cancer Treat Res. 2009;152:319-38. doi: 10.1007/978-1-4419-0284-9_17. Cancer Treat Res. 2009. PMID: 20213399 Review.
Cited by
-
Challenges of osteosarcoma care in Africa: a scoping review of the burden, management and outcome.Ecancermedicalscience. 2025 Jan 23;19:1835. doi: 10.3332/ecancer.2025.1835. eCollection 2025. Ecancermedicalscience. 2025. PMID: 40177151 Free PMC article. Review.
-
Age-dependent molecular variations in osteosarcoma: implications for precision oncology across pediatric, adolescent, and adult patients.Front Oncol. 2024 May 22;14:1382276. doi: 10.3389/fonc.2024.1382276. eCollection 2024. Front Oncol. 2024. PMID: 38841159 Free PMC article.
-
Ewing sarcoma outcomes in a country with limited resources: Egypt as an example.Am J Cancer Res. 2021 Jun 15;11(6):3212-3226. eCollection 2021. Am J Cancer Res. 2021. PMID: 34249456 Free PMC article.
-
Global, regional, and national burden of malignant neoplasm of bone and articular cartilage in adults aged 65 years and older, 1990-2021: a systematic analysis based on the global burden of disease study 2021.Aging Clin Exp Res. 2025 Jan 8;37(1):21. doi: 10.1007/s40520-024-02926-0. Aging Clin Exp Res. 2025. PMID: 39776003 Free PMC article.
-
Outcomes of comprehensive treatment for primary osteosarcoma.SAGE Open Med. 2020 May 20;8:2050312120923177. doi: 10.1177/2050312120923177. eCollection 2020. SAGE Open Med. 2020. PMID: 32547749 Free PMC article.
References
-
- Niu X, Xu H, Inwards CY, et al. Primary bone tumors: epidemiologic comparison of 9200 patients treated at Beijing Ji Shui Tan hospital, Beijing, China, with 10 165 patients at Mayo Clinic, Rochester, Minnesota. Arch Pathol Lab Med. 2015;139:1149–1155.
-
- Taran SJ, Taran R, Malipatil NB. Pediatric osteosarcoma: an updated review. Indian J Med Paediatr Oncol. 2017;38:33–43.
-
- Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer. 2009;115:1531–1543.
-
- Toepfer A, Salzmann M, Schauwecker J, et al. Primary malignant bone tumors. Orthopade. 2011;40:1121–1142.
-
- Dorfman HD, Czerniak B. Bone cancers. Cancer. 1995;75(suppl 1):203–210.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical